Bempedoic Acid API Market

Key data points: Market size in 2027 = $160 million and 2035 = $432 million, growth forecast = 13.2% annually for the next 8 years. Scroll below to get more insights. This market report covers trends, opportunities and forecasts in bempedoic acid API market to 2035 by type (pharmaceutical-grade API, modified-release API, combination-ready API, and experimental-grade API), application (standalone cholesterol-lowering drugs, combination therapies, and investigational formulations), end use (pharmaceutical manufacturers, contract research organizations, biotech firms, and hospitals & laboratories), and region (North America, Europe, Asia Pacific, and the Rest of the World) Bempedoic Acid API Market The future of the global bempedoic acid api market looks promising with opportunities in the pharmaceutical manufacturer, contract research organization, biotech firm, and hospital & laboratory markets. The global bempedoic acid api market is expected to reach an estimated $432 million by 2035 from $160 million in 2027 with a CAGR of 13.2% from 2027 to 2035. The major drivers for this market are the increasing prevalence of cardiovascular diseases, the rising demand for cholesterol-lowering therapies, and the growing adoption of advanced treatment options. • Lucintel forecasts that, within the type category, pharmaceutical-grade API is expected to witness the highest growth over the forecast period due to the pharma industry is focused on stringent quality requirements for pharmaceutical grade active pharmaceutical ingredients (apis). • Within the end use category, pharmaceutical manufacturers is expected to witness the highest growth over the forecast period due to the pharmaceutical industry has shown increasing interest in the development of cholesterol-lowering drugs. • In terms of regions, North America is expected to witness the highest growth over the forecast period due to high prevalence of cardiovascular diseases, in combination with an effective and efficient pharma industry. Gain valuable insights for your business decisions with our comprehensive 150+ page report. Sample figures with some insights are shown below. Emerging Trends in Bempedoic Acid API Market Between 2025 and 2027, the bempedoic acid api market is expected to change in ways that will require longer-term, more infrastructure and resources, and larger-scale operations. The developments that occur during this time will create greater options for customers that are not tied to a single supplier and will require greater regulatory compliance. Lucintel's report addresses these changes. • Different Supply Sources: From 2025 to 2027, customers will have the option to use suppliers from different regions, and will no longer need to rely on a single source. • Improved Production: Continuous processing and real time monitoring will allow manufacturers of the 2025-2027 time frame to better control impurity levels and crystallization. This will increase the uniformity of production batches. • Regulatory-grade Quality Systems: By 2025, we anticipate further investment in electronic batch records, data integrity, and risk management. Demand for these systems and methods will increase as customer validation becomes critical for retaining customers and expediting time to market. • Evidence-based Demand Planning: Results from the CLEAR Outcomes study showed that there is potential for bempedoic acid to address the needs of the statin-intolerant patient population. Between 2025 and 2027, we expect the generation of real world evidence to further document the benefits of bempedoic acid and guide its prescription. • Life Cycle and Combination: From 2025, we expect market competitors to extend their product portfolios through combination products and to protect their market position through the introduction of fixed dose combinations and other oral forms. Our focus will be on customers who anticipate and require long-term evidence for compliance. Through a discipline-led approach to the market, we anticipate that demand will be sustained as patients currently without effective treatment options gain access to new therapies. To achieve this, we believe it will be critical for manufacturers to implement process and quality controls and to be prepared for varying demand in different geographies. Recent Developments in the Bempedoic Acid API Market Bempedoic acid API market dynamics improved between 2025-2027 with the publication of cardiovascular guidelines, the launch of combination products, and expansion of market Protection synchronization. According to Lucintel, accessibility has evolved to be more important than discovery in the case formulation of the bempedoic acid market. Pharmaceutical companies have initiated technology transfer to control cost and improve access to established capacity for production of bempedoic acid. • Label-driven Indication: As of January 2025, Nexletol had label to treat adults to reduce LDL-C and bempedoic acid had label to treat adults to reduce LDL-C in patients who are not able to tolerate statins. Both indications led to increased demand of the API. Bempedoic acid is prescribed by health care professionals for primary and/or secondary prevention and hence increased the use beyond the specialty setting. • Outcome Data: The ongoing CLEAR Outcomes Study enrolled 13,970 statin intolerant patients and has positively influenced the at-risk evidence for payers and health care professionals. Outcome data for non-statin therapies has reduced payer and health care professional barriers and facilitated the use of such therapies. • Traditional Product Commercialization: Fixed dose combinations of bempedoic acid with ezetimibe continue to be an important growth opportunity. Meanwhile, layered therapy with LDL-C lowering drugs is becoming more prevalent. By 2025, the combination product consisting of two components would be available as a single pill, catalysing the interest of pharmaceutical companies in the production of individual components. • Preparation for Gen.D Product: In 2025, many companies involved in the manufacture and development of pharmaceuticals continued to create abbreviated forms and other regional, legal forms of marketing authorization for products containing a single active pharmaceutical ingredient. The first company to do so would benefit from a price-eroding generic marketing strategy. However, the company would benefit from the demand created by a lowered price ceiling. • Investment and Import/Export: In 2024-25, the Indian pharmaceutical industry continued large scale investment in producing active pharmaceutical ingredients (API) in regulated markets. As a result, the export of pharmaceutical products from India increased to US$ 27 billion. Increased investment in the production of bempedoic acid, coupled with easing supply constraints, is likely. However, there are significant barriers to large scale production of bempedoic acid. In the next three to five years, the price of bempedoic acid is expected to be low because of expected reimbursement and generic drugs. Expected changes in the industry may encourage broader prescription of bempedoic acid. Manufacturers that are able to produce bempedoic acid at an acceptable cost and quality will benefit. Strategic Growth Opportunities in the Bempedoic Acid API Market Bempedoic acid APIs are in an early stage of commercial development and positive changes are being witnessed in the market. Acceptance and recognition of oral non-statin therapies, recent updates in statin guidelines and recognition of statin intolerance have all created a positive environment for bempedoic acid. According to Lucintel, the market will remain competitive until 2026 because of the focus on the availability and consistent enhancement of the quality of bempedoic acid APIs. From 2026, new customers in different regions will be the main focus of the competitors. • Statin-intolerant Patient Therapies: Positive trends are expected for bempedoic acid combinations beyond the scope of traditional therapies for lowering LDL levels. The outlook for Esperion for net product sales in the range of $480-$510 million for the year 2025 created a lot of optimism for the company. New product launches for oral LDL lowering therapies are expected in the coming years. • Generic and Regional Formulations: Further, given the patency of some of the core bempedoic acid APIs, opportunities exist to make revenue by supplying the APIs to generic C sufficient tablets and/or fixed dose combinations. The Indian Pharmaceutical industry is well positioned to supply bempedoic acid APIs for pharmaceutical forms and dosages approved elsewhere, as it has developed the required regulatory and pharmaceutical know-how and forms. The Indian Pharmaceutical exports reached $27.9 billion in the first three quarters of 2024. • Combination Product Development: Some suppliers of active pharmaceutical ingredients (APIs) of bempedoic acid and ezetimibe offer support for the development of combination products. The US Food and Drug Administration (FDA) approved a combination of the two APIs in March 2020 and the product, Nexlizet, is the first of its kind in the market. There is potential for the combination product to gain traction in the market as sponsoring companies look to simplify product routes and enhance LDL-C lowering. • Untapped Market Potential: There are many underserved markets in the Latin American, Middle Eastern, and Southeast Asian regions where cardiovascular disease is prevalent. Local marketing authorizations and supply agreements will encourage other sponsoring companies to source bempedoic acid, strengthening the demand outlook for the short to medium term. • Client-focused Custom Manufacturing: Benefitting from outsourcing trends, custom manufacturing organizations can expect a positive outlook in the pharmaceutical market. Compliance to ICH Q7 remained the same in the recent amendment of 2025. Continuity of supply and managing active pharmaceutical ingredient (API) impurities positively impacts business and gives a competitive edge. Because of the nature of the market, manufacturers cannot rely on the volume of sales of APIs to be profitable. Manufacturers can depend on the clinical novelty of the products, reimbursement, and the certainty of a reliable and manufacturing partner to improve the commercial prospects. Simultaneously, manufacturers can focus on the development of reimbursed formulations. The demand for such products will no doubt increase, and while this is the case, prices will decrease as more manufacturers qualify to supply the products. Bempedoic Acid API Market Drivers and Challenges The increasing incidence of Cardiovascular Diseases creates opportunities for the use of bempedoic acid. As the cases of Hypercholesterolemia and the related CVD risk increase, more patients become amenable to treatment with bempedoic acid. In 2025 the World Health Organization (WHO) estimated that CVDs accounted for 17.9 million of the global annual mortality. The factors responsible for driving this market include: • The Need for Alternative Cholesterol Lowering Therapies: Statins remain the primary means to lower LDL, however, many patients are unable to tolerate or do not respond to statin therapy. For these patients, bempedoic acid may provide an alternative. Additionally, some patients may require an even greater reduction in LDL, and these patients too may be treated with bempedoic acid. • Increasing Utilization of Oral Therapies: As bempedoic acid is an oral therapy and may offer patients an improved quality of life as compared to parenteral therapies, it may also be employed to reduce LDL in patients who require such a reduction. • Statin Intolerance Demand: As a lipid-lowering therapy that does not increase the risk of myopathy, bempedoic acid has the potential to benefit patients that experience myopathy with statin therapy. Non-statin therapy options for patients that do not achieve their LDL-C goals continue to be discussed within clinical practice. In February 2025, bempedoic acid was discussed as an option to reduce LDL-C by approximately 20% as a monotherapy. Within the next 3 to 5 years, bempedoic acid will be continuously purchased, as more healthcare professionals become knowledgeable with the drug, and it becomes used in later lines of therapy. • Product Innovation: The creation of a single-dose combination of bempedoic acid and ezetimibe has improved the convenience of lowering LDL-C and increasing the demand for related pharmaceutical ingredients. In January 2025, single-dose combination products containing the two drugs were available. Within the next 3 to 5 years, continued research and development will increase the combination products and lower LDL-C, thereby increasing the demand and capabilities of the pharmaceutical industry. • Regulatory Acceptance: In April 2025, bempedoic acid continued to be approved to lower LDL-C in adults when other means to do so are unsuccessful. The regulatory burdens to develop the drug, and additional clinical evidence to support it, have decreased. During the next 3 to 5 years, sponsoring organizations will invest to create validated pharmaceutical ingredients of bempedoic acid, and establish supply agreements, based on the expected demand. The challenges facing this market include: • Costs To Produce Bempedoic Acid Remain High Compared To Mature Generics: In May 2025, many pharmaceutical companies continued to require a number of release tests before the final commercial distribution of a product, which increased both the time and cost of capital tied up in work in progress. It is possible that cost-sensitive customers will be reluctant to purchase the drug and may rely on a single supplier for many years. • Price Fluctuation and Lead Time Concerns: The raw materials for bempedoic acid are controlled by a small number of producers and are located in different parts of the world. The same is true for the final product. In July 2025, many pharmaceutical companies still relied on an outside supplier to provide raw materials for their products within 30 days. Over the next several years, it is possible that many pharmaceutical companies will produce different versions of bempedoic acid to satisfy customer demand in a given geographic location. • Competitive and Regulatory Pressures: Bempedoic acid is in the same therapeutic class as statins, PCSK9 inhibitors, ezetimibe and other emerging lipid lowering therapies. Simultaneously, Active Pharmaceutical Ingredients (APIs) producers face heightened documentation requirements. In September 2025, regulatory focus remained on lifecycle management, data integrity and pharmaceutical manufacturing traceability. Simultaneously, price and non-price competition negatively impacts supplier margins. The highest-quality and most reliable API producers are best positioned to grow market share. These effects are expected to persist over the next three to five years. The rising prevalence of CVD and statin intolerance as well as the acceptance of drug combinations and other advanced medical devices create a more favorable market condition for bempedoic acid. Other market challenges, such as price and competition, will also be influenced by supplier capability to control and meet the requirements of various regulations. The greatest opportunity will be realized by companies which have the ability to produce bempedoic acid of consistent quality at an affordable price over the next three to five years. List of Bempedoic Acid API Market Companies Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies bempedoic acid api market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the bempedoic acid api market companies profiled in this report include- • Esperion Therapeutics, Inc. • Lonza Group AG • Apotex Inc. • Hovione LLC • Zhejiang Hisun Pharmaceutical Co., Ltd. • Teva Pharmaceutical Industries Ltd. • WuXi AppTec Co., Ltd. • Samsung Biologics Co., Ltd. • Dr. Reddy’s Laboratories Ltd. • Ajanta Pharma Ltd. Bempedoic Acid API Market by Segment The study includes a forecast for the global bempedoic acid api market by type, application, end use, and region. Bempedoic Acid API Market by Type [Value ($M) from 2019 to 2035]: • Pharmaceutical-grade API • Modified-release API • Combination-ready API • Experimental-grade API Bempedoic Acid API Market by Application [Value ($M) from 2019 to 2035]: • Standalone Cholesterol-lowering Drugs • Combination Therapies • Investigational Formulations Bempedoic Acid API Market by End Use [Value ($M) from 2019 to 2035]: • Pharmaceutical Manufacturers • Contract Research Organizations • Biotech Firms • Hospitals & Laboratories Bempedoic Acid API Market by Region [Value ($M) from 2019 to 2035]: • North America • Europe • Asia Pacific • The Rest of the World Country Wise Outlook for the Bempedoic Acid API Market The marketing of bempedoic acid API is changed because of regulatory changes, more local pharmaceutical production, and more non-statin use. From 2025 to 2027, drug companies will ensure there is enough bempedoic acid to manufacture both branded and generic drugs, and think about how to bring their products to different national markets. According to recent market research by Lucintel, changes in the market will occur based on the strategies used by companies to bring their products to the market and on the companies’ supply chain. • United States: Marketing will be company-led. As of now, the only companies marketing bempedoic acid are Esperion (makers of NEXLETOL and NEXLIZET), and the FDA. NEXLETOL and NEXLIZET each have 180 mg of bempedoic acid per pill, and the FDA has recently approved (March 2024) NEXLIZET to lower cardiovascular risk. Pharmacies are currently planning for the 2025 purchase and distribution cycle. It is likely that NEXLIZET will be prescribed more for statin-intolerant patients to reduce cardiovascular risk. This should lead to an increase in the volume of NEXLIZET and other bempedoic acid-based medications sold and produced in the U.S. and elsewhere. • China: Regulatory changes and local production. Companies in China are producing bempedoic acid to combine with other cholesterol-lowering drugs and other cardiovascular drugs. The Chinese Drug Administration recently approved the use of domestically produced drugs to offset the use of imported drugs. It is likely that China will approve the use of bempedoic acid to lower cholesterol and other cardiovascular drugs. Local drug and pharmaceutical production will encourage other regional production. • Germany: Position in the EU centralized procedure: NILEMDO and NUSTENDI contain 180 mg bempedoic acid. Reimbursement and prescribing activities by the German Health Authority have been of interest to suppliers in 2025. With Germany being the largest national pharmaceutical market in the EU, the availability of this drug in the country may impact other EU member states and affect the supply and the raw material for the drug. • India: Production and Exports: In 2025, Indian pharma companies finalized CV Generics and CD programs to include bempedoic acid (180 mg). This establishes a market benchmark. This information is relevant as India is well positioned to provide affordable and good quality bempedoic acid CV products to both developed and developing nations. • Japan: Similar to other countries, regulatory and pharma companies in Japan are evaluating non-statin lipid-lowering drugs. As of 2025, 180 mg bempedoic acid was the standard throughout the world. Japan may also encourage other countries in the region to evaluate the drug. Features of the Global Bempedoic Acid API Market Market Size Estimates: bempedoic acid api market size estimation in terms of value ($B). Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions. Segmentation Analysis: bempedoic acid api market size by type, application, end use, and region in terms of value ($B). Regional Analysis: bempedoic acid api market breakdown by North America, Europe, Asia Pacific, and Rest of the World. Growth Opportunities: Analysis of growth opportunities in different type, application, end use, and regions for the bempedoic acid api market. Strategic Analysis: This includes M&A, new product development, and competitive landscape of the bempedoic acid api market. Analysis of competitive intensity of the industry based on Porter’s Five Forces model. If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more. This report answers following 11 key questions: Q.1. What are some of the most promising, high-growth opportunities for the bempedoic acid api market by type (pharmaceutical-grade API, modified-release API, combination-ready API, and experimental-grade API), application (standalone cholesterol-lowering drugs, combination therapies, and investigational formulations), end use (pharmaceutical manufacturers, contract research organizations, biotech firms, and hospitals & laboratories), and region (North America, Europe, Asia Pacific, and the Rest of the World)? Q.2. Which segments will grow at a faster pace and why? Q.3. Which region will grow at a faster pace and why? Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market? Q.5. What are the business risks and competitive threats in this market? Q.6. What are the emerging trends in this market and the reasons behind them? Q.7. What are some of the changing demands of customers in the market? Q.8. What are the new developments in the market? Which companies are leading these developments? Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth? Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution? Q.11. What M&A activity has occurred in the last 8 years and what has its impact been on the industry?